1. Lipid Clinic Challenge

2. Who is Vulnerable and Why

3. JUPITER Increased Incidence of T2D With Rosuvastatin

4. Hypotheses

5. T2D Risk Increases With Statin Potency Meta-Analysis of 5 Clinical Trials

6. WOSCOPS Pravastatin Reduction in LDL-C/Reduced CAD by 30%

7. Statins and the Development of Diabetes[a,b]

8. JUPITER Rosuvastatin Therapy and Diabetes Risk[a,b]

9. Obesity and Metabolic Syndrome

10. Analysis of 3 Atorvastatin Trials (TNT, SPARCL, and IDEAL)

11. Don't Just Blame Statins

12. 2013 ACC/AHA Cholesterol Guidelines Statin Initiation Recommendations

13. REAL-CAD: Primary Endpoint CV Death/MI/Ischemic Stroke/UA

14. J-PREDICT Primary Outcome: Cumulative Incidence of Diabetes

15. ABCA1: A Very Important Transmembrane HDL Binding Protein

16. Pitavastatin: No Elevation in Serum Glucose

17. Managing Cardiovascular Risk

18. Hepatic Steatosis and Insulin Resistance

19. Effects of Pitavastatin on Insulin Sensitivity and Liver Fat

20. Case Study: Patient With Obesity With Hypertension and Dyslipidemia

21. Case Study: Patient With Obesity With Hypertension and Dyslipidemia

22. Many Issues at Play: Education is Needed

23. It Takes a Team

24. Abbreviations

25. Abbreviations (cont)